Outcomes of patients with pelvic leiomyosarcoma treated by surgery and relevant auxiliary diagnosis

Table 2 Serum tumor markers and medical imaging examinations of pelvic leiomyosarcoma patients

Characteristic	Uterine leiomyosarcoma (n = 35)	Non-uterine leiomyosarcoma (n = 16)
Serum tumor markers, n (%)
CA125	21 (60)	11 (68.8)
Elevated	6 (28.6)	5 (45.5)
Not elevated	15 (71.4)	6 (54.5)
CEA	15 (42.9)	7 (63.6)
Elevated	1 (6.7)	0 (0)
Not elevated	14 (93.3)	7 (100)
AFP	14 (40)	7 (63.6)
Elevated	0 (0)	0 (0)
Not elevated	14 (100)	7 (100)
CA199	12 (34.3)	7 (63.6)
Elevated	0 (0)	0 (0)
Not elevated	12 (100)	7 (100)
CA153	5 (14.3)	0 (0)
Elevated	0 (0)	—
Not elevated	5 (100)	—
CA724	5 (14.3)	0 (0)
Elevated	2 (40)	—
Not elevated	3 (60)	—
Medical imaging examination, n (%)
Ultrasonography	16 (45.7)	11 (68.8)
Hysteromyoma	11 (68.8)	1 (9.1)
Pelvic and abdominal mass	4 (25)	8 (72.7)
Malignant occupancy of cervix	1 (6.2)	2 (18.2)
CT	2 (5.7)	1 (6.3)
MRI	1 (2.9)	0 (0)

CA: Carbohydrate antigen; CEA: Carcinoembryonic antigen; CT: Computed tomography; MRI: Magnetic resonance imaging.